COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı

Özdemir, Öner; AŞIR, Ayşegül Pala

doi:10.31832/smj.933390

COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı

Öner ÖZDEMİR, (Sakarya Üniversitesi, Tıp Fakültesi, Sakarya Eğitim ve Araştırma Hastanesi, Çocuk İmmünolojisi ve Alerji Hastalıkları Bilim Dalı, Sakarya, Türkiye)

Ayşegül PALA (Sağlık Bilimleri Üniversitesi, Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı, Diyarbakır, Türkiye)

Sakarya Tıp Dergisi

14 8

Yıl: 2022 Cilt: 12 Sayı: 1 Sayfa Aralığı: 193 - 201 Metin Dili: Türkçe DOI: 10.31832/smj.933390 İndeks Tarihi: 29-07-2022

COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı

Öz:

Aralık 2019 yılında Çin’in Wuhan şehrinde etiyolojisi bilinmeyen bir pnömoni salgını tüm dünyaya yayıldı. Bu salgın yeni tip koronavirüs olan Şiddetli Akut Solunum Sendromu Coronavirus 2 (SARS-CoV-2) olarak adlandırıldı ve hastalığa COVID-19 adı verildi. Dünya Sağlık Örgütü (DSÖ) tarafından global pandemi ilan edildi. COVID -19 hastalığında ateş, öksürük, krup, nefes darlığı, koku alamama gibi semptomların yanında gastrointestinal sistem hastalıkların (GİS) semptomları da bildirilmiştir. SARS-CoV-2, akciğerlerin alveolar epitel hücrelerinde bulunan ACE-2 reseptörlerine bağlanarak pnömoniye neden olur. Ayrıca sadece akciğer hücreleri değil bağırsak epitel hücrelerinin (özellikle enterositler) de ACE-2 reseptörlerini eksprese ettiği gözlenmiştir. Son zamanlarda COVID-19 hastalarının dışkı materyalinde de SARS-CoV-2 RNA izole edilmiştir. Bu durum COVID-19 ve GİS arasında bir ilişki olabileceğini göstermektedir. Şu anda, COVID-19 için kullanılan ilaç ve birden fazla aşı mevcuttur ancak aşı üretimi, aşının etkinliği, saklama koşulları ve taşınmasındaki aksaklıklardan dolayı viral yükü azaltmak için alternatif tedaviler araştırılmaktadır. Probiyotikler, belirli dozlarda insan sağlığı üzerine faydalı etkileri olan canlı mikroorganizmalar olarak tanımlanmaktadır. Bilimsel çalışmalar probiyotiklerin antiviral özelliğini ve genel bağışıklığı güçlendirici etkisini ortaya koymuştur. Bu derleme probiyotiklerin COVID-19 hastalığındaki rolünü, SARS-CoV-2 enfeksiyonu ve mikrobiyota arasındaki olası ilişkiyi tartışmayı amaçlamaktadır.

Anahtar Kelime: COVID-19 probiyotikler mikrobiyota bağırsak-akciğer aksı

THE ROLE, IMPORTANCE AND USE OF PROBIOTICS IN COVID-19 DISEASE

Öz:

In December 2019, a pneumonia epidemic of unknown etiology spread to the whole world in Wuhan, China. This epidemic was named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the new type of coronavirus, and the disease was named COVID-19. It has been declared a global pandemic by the World Health Organization (WHO). In COVID-19 disease, symptoms such as fever, cough, croup, shortness of breath, and inability to smell have been reported, as well as symptoms of gastrointestinal system diseases (GIS). SARS-CoV-2 causes pneumonia by binding to ACE-2 receptors found in alveolar epithelial cells of the lungs. It has also been observed that not only lung cells but also intestinal epithelial cells (especially enterocytes) express ACE-2 receptors. Recently, SARS-CoV-2 RNA has also been isolated in the stool material of COVID-19 patients. This indicates that there may be a relationship between COVID-19 and GIS. Currently, there are drugs and multiple vaccines used for COVID-19, but alternative treatments are being explored to reduce viral load due to insufficiency in vaccine production, vaccine efficacy, storage conditions and transportation. Probiotics are defined as living microorganisms that, in certain doses, have beneficial effects on human health. Scientific studies have revealed the antiviral properties and general immunity-enhancing effects of probiotics. This review aims to discuss the role of probiotics in COVID-19 disease, the possible relationship between SARS-CoV-2 infection and the microbiota.

Anahtar Kelime: probiotics

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Ozdemir O, Pala A. Çocuklarda COVID-19 Enfeksiyonunun Tanısı, Tedavisi ve Korunma Yolları. Journal of Biotechnology and Strategic Health Research 2020;1(Özel sayı):14-21.
2. Th e Johns Hopkins University School of Medicine CRC. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2021 [cited 2021 April 25].
3. Baud D, Dimopoulou Agri V, Gibson GR, Reid G, Giannoni E. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. Front Public Health 2020;8:186.
4. Chen ZL, Zhang C, Yin J, Xin X, Li HM, Wang YP, et al. Challenges and opportunities for ovarian cancer management in the epidemic of Covid-19: lessons learned from Wuhan, China. Journal of Ovarian Research 2021;14(1):35.
5. Sadiq FA. Is it time for microbiome-based therapies in viral infections? Virus Research 2021;291:198203.
6. Antunes AEC, Vinderola G, Xavier-Santos D, Sivieri K. Potential contribution of beneficial microbes to face the COVID-19 pandemic. Food Res Int 2020;136:109577.
7. Muñoz-Carrillo JL, Contreras-Cordero J, Gutierrez O, Villalobos-Gutiérrez P, Ramos-Gracia L, Hernández-Reyes V. Cytokine Profiling Plays a Crucial Role in Activating Immune System to Clear Infectious Pathogens. In Tyagi RK and Bisen PS (eds), Immune Response Activation and Immunomodulation. IntechOpen, 2018 (epub).
8. Cytokines in the balance. Nature Immunology 2019;20(12):1557-1557.
9. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. Cureus 2020;12(3):e7355.
10. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Journal of Virology 2020;94(7):e00127-20.
11. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Medicine 2020;8(4):420-422.
12. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. Th e cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine & Growth Factor Reviews 2020;53:25-32.
13. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology 2020;159(3):944-955.
14. Jin X, Lian J-S, Hu J-H, Gao J, Zheng L, Zhang Y-M, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69(6):1002-1009.
15. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res 2020;285:198018.
16. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006;312(5778):1355-1359.
17. Villanueva-Millan MJ, Perez-Matute P, Oteo JA. Gut microbiota: a key player in health and disease. A review focused on obesity. Journal of Physiology and Biochemistry 2015;71(3):509-525.
18. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nature Reviews Immunology 2016;16(6):341-352.
19. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, et al. Alteration of Gut Microbiota in Infl ammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens 2019;8(3):126.
20. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. Ebiomedicine 2020;51:102590.
21. Bingula R, Filaire M, Radosevic-Robin N, Bey M, Berthon J-Y, Bernalier-Donadille A, et al. Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. Journal of Oncology 2017;2017:5035371.
22. Zhang Q, Li X, Liu X, Dong M, Xiao J, Wang J, et al. Association between maternal antimony exposure and risk of gestational diabetes mellitus: a birth cohort study. Chemosphere 2020;246:125732.
23. Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal infl ammatory disease. Mucosal Immunology 2012;5(1):7-18.
24. Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. Th e role of the lung microbiota and the gutlung axis in respiratory infectious diseases. Cellular Microbiology 2018;20(12):e12966.
25. Fanos V, Pintus MC, Pintus R, Marcialis MA. Lung microbiota in the acute respiratory disease: from coronavirus to metabolomics. Journal of Pediatric and Neonatal Individualized Medicine 2020; 9(1):e090139.
26. Sundararaman A, Ray M, Ravindra PV, Halami PM. Role of probiotics to combat viral infections with emphasis on COVID-19. Applied Microbiology and Biotechnology 2020;104(19):8089-8104.
27. Fontana L, Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, Gil A. Sources, isolation, characterisation and evaluation of probiotics. British Journal of Nutrition 2013;109(Suppl 2):S35-S50.
28. Plaza-Diaz J, Javier Ruiz-Ojeda F, Gil-Campos M, Gil A. Mechanisms of Action of Probiotics. Advances in Nutrition 2019;10(suppl_1):S49-S66.
29. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial eff ects. Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology 2002;82(1-4):279-289.
30. Park DM, Bae J-H, Kim MS, Kim H, Kang SD, Shim S, et al. Suitability of Lactobacillus plantarum SPCSNU 72-2 as a Probiotic Starter for Sourdough Fermentation. Journal of Microbiology and Biotechnology 2019;29(11):1729-1738.
31. Ren D, Li C, Qin Y, Yin R, Du S, Liu H, et al. Evaluation of immunomodulatory activity of two potential probiotic Lactobacillus strains by in vivo tests. Anaerobe 2015;35(Pt B):22-27.
32. Seddik HA, Bendali F, Gancel F, Fliss I, Spano G, Drider D. Lactobacillus plantarum and Its Probiotic and Food Potentialities. Probiotics and Antimicrobial Proteins 2017;9(2):111-122.
33. Ren D-Y, Li C, Qin Y-Q, Yin R-L, Du S-W, Ye F, et al. Lactobacilli Reduce Chemokine IL-8 Production in Response to TNF-alpha and Salmonella Challenge of Caco-2 Cells. Biomed Research International 2013;2013:925219.
34. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, Prebiotics and Immunomodulation of Gut Mucosal Defences: Homeostasis and Immunopathology. Nutrients 2013;5(6):1869-1912.
35. Starosila D, Rybalko S, Varbanetz L, Ivanskaya N, Sorokulova I. Anti-infl uenza Activity of a Bacillus subtilis Probiotic Strain. Antimicrobial Agents and Chemotherapy 2017;61(7):e00539-17.
36. Mahooti M, Abdolalipour E, Salehzadeh A, Mohebbi SR, Gorji A, Ghaemi A. Immunomodulatory and prophylactic eff ects of Bifidobacterium bifidum probiotic strain on infl uenza infection in mice. World Journal of Microbiology & Biotechnology 2019;35(6):91.
37. Lehtoranta L, Pitkaranta A, Korpela R. Probiotics in respiratory virus infections. European Journal of Clinical Microbiology & Infectious Diseases 2014;33(8):1289-1302.
38. Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, Gomez-Llorente C, Gil A. Probiotic Mechanisms of Action. Annals of Nutrition and Metabolism 2012;61(2):160-174.
39. Mastromarino P, Cacciotti F, Masci A, Mosca L. Antiviral activity of Lactobacillus brevis towards herpes simplex virus type 2: Role of cell wall associated components. Anaerobe 2011;17(6):334-336.
40. An HM, Lee DK, Kim JR, Lee SW, Cha MK, Lee KO, et al. Antiviral activity of Bifidobacterium adolescentis SPM 0214 against herpes simplex virus type 1. Archives of Pharmacal Research 2012;35(9):1665-1671.
41. Chen CC, Baylor M, Bass DM. MURINE INTESTINAL MUCINS INHIBIT ROTAVIRUS INFECTION. Gastroenterology 1993;105(1):84-92.
42. Kim JJ, Khan WI. Goblet cells and mucins: role in innate defense in enteric infections. Pathogens 2013;2(1):55- 70.
43. Luoto R, Ruuskanen O, Waris M, Kalliomaki M, Salminen S, Isolauri E. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology 2014;133(2):405-413.
44. Turner RB, Woodfolk JA, Borish L, Steinke JW, Patrie JT, Muehling LM, et al. Eff ect of probiotic on innate infl ammatory response and viral shedding in experimental rhinovirus infection - a randomised controlled trial. Beneficial Microbes 2017;8(2):207-215.
45. Dongarra ML, Rizzello V, Muccio L, Fries W, Cascio A, Bonaccorsi I, et al. Mucosal Immunology and Probiotics. Current Allergy and Asthma Reports 2013;3(1):19-26.
46. Jiang T, Zhang H, Xu X, Li H, Yang J. Mixed probiotics decrease the incidence of stage II-III necrotizing enterocolitis and death: A systematic review and meta-analysis. Microbial Pathogenesis 2020;138:103794.
47. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. New England Journal of Medicine 2020;382(21):1969-1973.
48. Villena J, Guadalupe Vizoso-Pinto M, Kitazawa H. Intestinal Innate Antiviral Immunity and Immunobiotics: Beneficial Eff ects against Rotavirus Infection. Frontiers in Immunology 2016;7: 563.
49. Grizotte-Lake M, Zhong G, Duncan K, Kirkwood J, Iyer N, Smolenski I, et al. Commensals Suppress Intestinal Epithelial Cell Retinoic Acid Synthesis to Regulate Interleukin-22 Activity and Prevent Microbial Dysbiosis. Immunity 2018;18;49(6):1103-1115.e6.
50. Dermyshi E, Wang Y, Yan C, Hong W, Qiu G, Gong X, et al. Th e “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants. Neonatology 2017;112(1):9-23.
51. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, et al. Eff ect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B-bifidum MF 20/5 on common cold episodes: A double blind, randomized, controlled trial. Clinical Nutrition 2005;24(4):481-491.
52. Waki N, Matsumoto M, Fukui Y, Suganuma H. Eff ects of probiotic Lactobacillus brevis KB290 on incidence of infl uenza infection among schoolchildren: an open-label pilot study. Letters in Applied Microbiology 2014;59(6):565-571.
53. Su M, Jia Y, Li Y, Zhou D, Jia J. Probiotics for the Prevention of Ventilator-Associated Pneumonia: A Meta-Analysis of Randomized Controlled Trials. Respiratory Care 2020;65(5):673-685.
54. Veckman V, Miettinen M, Pirhonen J, Siren J, Matikainen S, Julkunen I. Streptococcus pyogenes and Lactobacillus rhamnosus diff erentially induce maturation and production of Th 1-type cytokines and chemokines in human monocyte-derived dendritic cells. Journal of Leukocyte Biology 2004;75(5):764-771.
55. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, et al. Commensal Bacteria Calibrate the Activation Th reshold of Innate Antiviral Immunity. Immunity 2012;37(1):158-170.
56. Namba K, Hatano M, Yaeshima T, Takase M, Suzuki K. Eff ects of Bifidobacterium longum BB536 Administration on Infl uenza Infection, Infl uenza Vaccine Antibody Titer, and Cell-Mediated Immunity in the Elderly. Bioscience Biotechnology and Biochemistry 2010;74(5):939-945.
57. Chong H-X, Yusoff NAA, Hor Y-Y, Lew L-C, Jaafar MH, Choi S-B, et al. Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and infl ammatory parameters: A randomized, double-blind, placebo-controlled study. Journal of Dairy Science 2019;102(6):4783-4797.
58. Anwar F, Altayb HN, Al-Abbasi FA, Al-Malki AL, Kamal MA, Kumar V. Antiviral eff ects of probiotic metabolites on COVID-19. Journal of Biomolecular Structure & Dynamics 2020;1-10 (Epub ahead of print).
59. Din AU, Hassan A, Zhu Y, Yin T, Gregersen H, Wang G. Amelioration of TMAO through probiotics and its potential role in atherosclerosis. Applied Microbiology and Biotechnology 2019;103(23-24):9217-9228.
60. Manichanh C, Borruel N, Casellas F, Guarner F. Th e gut microbiota in IBD. Nature Reviews Gastroenterology & Hepatology 2012;9(10):599-608.
61. Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Scientific Reports 2019;9:4812.
62. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy - a randomised, double-blind, placebo-controlled study. British Journal of Nutrition 2009;101(11):1722-1726.
63. Smith TJ, Rigassio-Radler D, Denmark R, Haley T, Touger-Decker R. Eff ect of Lactobacillus rhamnosus LGG (R) and Bifidobacterium animalis ssp lactis BB-12 (R) on health-related quality of life in college students aff ected by upper respiratory infections. British Journal of Nutrition 2013;109(11):1999-2007.
64. Zhang H, Yeh C, Jin Z, Ding L, Liu BY, Zhang L, et al. Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. Synthetic and Systems Biotechnology 2018;3(2):113-120.
65. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et al. Randomised clinical trial: the eff ectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Alimentary Pharmacology & Th erapeutics 2012;35(3):327-334.
66. Chen MF, Weng KF, Huang SY, Liu YC, Tseng SN, Ojcius DM, et al. Pretreatment with a heat-killed probiotic modulates monocyte chemoattractant protein-1 and reduces the pathogenicity of infl uenza and enterovirus 71 infections. Mucosal Immunology 2017;10(1):215-227.
67. Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu L, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal infl ammation in mice through an EGFR-dependent mechanism. Journal of Clinical Investigation 2011;121(6):2242-2253.
68. Wypych TP, Wickramasinghe LC, Marsland BJ. Th e infl uence of the microbiome on respiratory health. Nature Immunology 2019;20(10):1279-1290.
69. Forsythe P. Probiotics and Lung Diseases. Chest 2011;139(4):901-908.
70. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama-Journal of the American Medical Association 2020;323(11):1061-1069.
71. Song Y, Liu P, Shi XL, Chu YL, Zhang J, Xia J, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut 2020;69(6):1143-1144.
72. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. FEEDING OF BIFIDOBACTERIUM-BIFIDUM AND STREPTOCOCCUS-THERMOPHILUS TO INFANTS IN-HOSPITAL FOR PREVENTION OF DIARRHEA AND SHEDDING OF ROTAVIRUS. Lancet 1994;344(8929):1046-1049.
73. Habib AMG, Ali MAE, Zouaoui BR, Taha MAH, Mohammed BS, Saquib N. Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Bmc Infectious Diseases 2019;19(1):870.
74. Zhang Y, Lu Z, Wang B, Cang J, Ma Y. Gastrointestinal tract symptoms in coronavirus disease 2019: Analysis of clinical symptoms in adult patients. medRxiv 2020 (preprint).
75. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy 2020;40(5):416-437.
76. Kalantar-Zadeh K, Ward SA, Kalantar-Zadeh K, El-Omar EM. Considering the Eff ects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles. Acs Nano 2020;14(5):5179-5182.
77. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nature Reviews Gastroenterology & Hepatology 2010;7(9):503-514.
78. Lourens-Hattingh A, Viljoen BC. Yogurt as probiotic carrier food. International Dairy Journal 2001;11(1- 2):1-17.

APA	Özdemir Ö, AŞIR A (2022). COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. , 193 - 201. 10.31832/smj.933390
Chicago	Özdemir Öner,AŞIR Ayşegül Pala COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. (2022): 193 - 201. 10.31832/smj.933390
MLA	Özdemir Öner,AŞIR Ayşegül Pala COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. , 2022, ss.193 - 201. 10.31832/smj.933390
AMA	Özdemir Ö,AŞIR A COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. . 2022; 193 - 201. 10.31832/smj.933390
Vancouver	Özdemir Ö,AŞIR A COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. . 2022; 193 - 201. 10.31832/smj.933390
IEEE	Özdemir Ö,AŞIR A "COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı." , ss.193 - 201, 2022. 10.31832/smj.933390
ISNAD	Özdemir, Öner - AŞIR, Ayşegül Pala. "COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı". (2022), 193-201. https://doi.org/10.31832/smj.933390

APA	Özdemir Ö, AŞIR A (2022). COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. Sakarya Tıp Dergisi, 12(1), 193 - 201. 10.31832/smj.933390
Chicago	Özdemir Öner,AŞIR Ayşegül Pala COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. Sakarya Tıp Dergisi 12, no.1 (2022): 193 - 201. 10.31832/smj.933390
MLA	Özdemir Öner,AŞIR Ayşegül Pala COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. Sakarya Tıp Dergisi, vol.12, no.1, 2022, ss.193 - 201. 10.31832/smj.933390
AMA	Özdemir Ö,AŞIR A COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. Sakarya Tıp Dergisi. 2022; 12(1): 193 - 201. 10.31832/smj.933390
Vancouver	Özdemir Ö,AŞIR A COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı. Sakarya Tıp Dergisi. 2022; 12(1): 193 - 201. 10.31832/smj.933390
IEEE	Özdemir Ö,AŞIR A "COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı." Sakarya Tıp Dergisi, 12, ss.193 - 201, 2022. 10.31832/smj.933390
ISNAD	Özdemir, Öner - AŞIR, Ayşegül Pala. "COVID-19 Hastalığında Probiyotiklerin Rolü, Önemi ve Kullanımı". Sakarya Tıp Dergisi 12/1 (2022), 193-201. https://doi.org/10.31832/smj.933390